The website may be down at times on Saturday, December 14, and Sunday, December 15, for maintenance. 

  • Clinical Guidance

    COPD: Clinical Guidance and Practice Resources

    Chronic obstructive pulmonary disease (COPD) affects around 15 million people in the U.S. and costs more than $32 billion annually.* Chronic lower respiratory diseases, including COPD, are the fourth leading cause of death in the U.S. and the third leading cause of death worldwide.** Family physicians are key players in managing COPD through diagnosis, treatment, and coordination of care.

    Screening Recommendations

    At this time, screening is not recommended by the USPSTF for COPD in asymptomatic adults. Read more

     

    Treatment and Management Recommendations

    Management of Acute Exacerbations of COPD
    Developed by the AAFP (April 2021)

    Management of Stable COPD: GOLD Guidelines
    The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a resource that provides a review of evidence with practice considerations and is widely used by clinicians in managing stable COPD. As this document is not a clinical practice guideline, it did not meet the criteria to be reviewed by the AAFP for endorsement.

    Managing Your Practice

    Quality Measures: Identify Opportunities to Improve Patient Care

    AAFP TIPS Topic on Quality Improvement
    Train your team on the benefits, concepts, and steps of the quality improvement process to enhance the care you provide. Includes two online learning courses, three customizable slide decks, and six downloadable tools. CME: 1 AAFP Prescribed credit; Free to members.

    Coding & Payment: How to Support Chronic Care Management Services  

    Coordinated Care and Care Management Tools and Resources

    FPM Journal
    Coding Common Respiratory Problems in ICD-10

    Implementation Tools and Considerations

    On-Demand Webcast: Spectrum of COPD Treatment
    This free recorded webcast covers best practices for care coordination, COPD co-morbidities, environmental factors, how social determinants of health influence the condition, and more.

     

    Pharmacologic Management of COPD Exacerbations

    Developed by the AAFP and approved in April 2021

    Education

    Other Related Resources


    * Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2014. Natl Vital Stat Rep. 2016;65(4):1-122. AND  #2. Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015; 147(1):31-45.

    ** Murphy SL, Xu J, Kochanek KD, et al. Mortality in the United States, 2017. NCHS Data Brief. 2018;(328):1-8. AND #4. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016 [published correction appears in Lancet. 2017;390(10106):e38]. Lancet. 2017;390(10100):1151-1210.